Detailed information for compound 1964992

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 548.072 | Formula: C31H34ClN3O4
  • H donors: 1 H acceptors: 2 LogP: 4.59 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 2
  • SMILES: COc1cc2CC(=O)N([C@H](c2cc1OC(C)C)c1ccc(cc1)Cl)c1ccc(cc1)[C@@H](N1CCNCC1=O)C
  • InChi: 1S/C31H34ClN3O4/c1-19(2)39-28-17-26-23(15-27(28)38-4)16-29(36)35(31(26)22-5-9-24(32)10-6-22)25-11-7-21(8-12-25)20(3)34-14-13-33-18-30(34)37/h5-12,15,17,19-20,31,33H,13-14,16,18H2,1-4H3/t20-,31-/m0/s1
  • InChiKey: AJYCGDGWEQCZPL-GEFUHLBYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens MDM2 proto-oncogene, E3 ubiquitin protein ligase Starlite/ChEMBL No references
Homo sapiens MDM4, p53 regulator Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Toxoplasma gondii SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5
Echinococcus granulosus Upstream activation factor subunit UAF30 0.0026 0.5 0.5
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Chlamydia trachomatis SWIB complex protein 0.0026 0.5 0.5
Brugia malayi brahma associated protein 60 kDa 0.0026 0.5 0.5
Echinococcus multilocularis Upstream activation factor subunit UAF30 0.0026 0.5 0.5
Schistosoma mansoni brg-1 associated factor 0.0026 0.5 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5
Toxoplasma gondii DNA topoisomerase domain-containing protein 0.0026 0.5 0.5
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Plasmodium vivax SWIB/MDM2 domain-containing protein, putative 0.0026 0.5 0.5
Loa Loa (eye worm) brahma associated protein 0.0026 0.5 0.5
Loa Loa (eye worm) SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5
Plasmodium vivax hypothetical protein, conserved 0.0026 0.5 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5
Brugia malayi SWIB/MDM2 domain containing protein 0.0026 0.5 0.5
Chlamydia trachomatis DNA topoisomerase I 0.0026 0.5 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0026 0.5 0.5
Echinococcus granulosus SWI:SNF matrix associated 0.0026 0.5 0.5
Onchocerca volvulus 0.0026 0.5 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 8580 nM BindingDB_Patents: Time Resolved Fluorescence Energy Transfer (TR-FRET) Assay. The inhibition of p53-Hdm2 and p53-Hdm4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfer (or Foerster resonance energy transfer) describes an energy transfer between donor and acceptor fluorescent molecules. For this assay, MDM2 protein (amino acids 2-188) and MDM4 protein (amino acids 2-185), tagged with a C-terminal Biotin moiety, are used in combination with a Europium labeled streptavidin (Perkin Elmer, Inc., Waltham, Mass., USA) serving as the donor fluorophore. The p53 derived, Cy5 labeled peptide Cy5-TFSDLWKLL (p53 aa 18-26) is the energy acceptor. Upon excitation of the donor molecule at 340 nm, binding interaction between MDM2 or MDM4 and the p53 peptide induces energy transfer and enhanced response at the acceptor emission wavelength at 665 nm. Disruption of the formation of the p53-MDM2 or p53-MDM4 complex due to an inhibitor molecule binding to the p53 binding site of MDM2 or MDM4 results in increased donor emission. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.